DexCom (DXCM) reported $1.04 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 12.5%. EPS of $0.32 for the same period compares to $0.32 a year ago.
The reported revenue represents a surprise of +1.99% over the Zacks Consensus Estimate of $1.02 billion. With the consensus EPS estimate being $0.33, the EPS surprise was -3.03%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how DexCom performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- International: $285.50 million compared to the $303.93 million average estimate based on six analysts. The reported number represents a change of +6.6% year over year.
- Revenue- United States: $750.50 million compared to the $709.42 million average estimate based on six analysts. The reported number represents a change of +14.9% year over year.
- Revenue- Hardware: $38.80 million versus the two-analyst average estimate of $38.39 million. The reported number represents a year-over-year change of -41.8%.
- Revenue- Sensor and other: $997.20 million versus the two-analyst average estimate of $978.78 million. The reported number represents a year-over-year change of +16.7%.
View all Key Company Metrics for DexCom here>>>
Shares of DexCom have returned +4.8% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
DexCom, Inc. (DXCM): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
